MedTrace Logo

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

NCT06372457 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 331

Last updated 2026-05-04

No results posted yet for this study

Summary

COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.

Conditions

  • Hypertrophic Cardiomyopathy (HCM)

Interventions

DRUG

Approved Hypertrophic Cardiomyopathy drug treatments

As per product label

DRUG

Mavacamten

As per product label

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2025-09-29
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06372457 on ClinicalTrials.gov